Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

asx vti

  • Home
  •  
  • asx vti



  • Most Read
  • Latest Comments
  • Visioneering Technologies NaturalVue contact lenses slow myopia – Study
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Visioneering Technologies NaturalVue contact lenses slow myopia – Study
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Visioneering Technologies NaturalVue contact lenses slow myopia – Study
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Visioneering Technologies NaturalVue contact lenses slow myopia – Study
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Visioneering Technologies NaturalVue contact lenses slow myopia – Study
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • PainChek locks in performance data for FDA submission, aiming to be  first pain assessment app approved in US
    PainChek locks in performance data for FDA submission, aiming to be first pain assessment app approved in US
    • News

  • HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    • News

  • dorsaVi secures $110k in contracts across mining, healthcare, and shipping sectors
    dorsaVi secures $110k in contracts across mining, healthcare, and shipping sectors
    • News

  • Compumedic hits record medtech diagnostics revenue with growth in US and China being targeted
    Compumedic hits record medtech diagnostics revenue with growth in US and China being targeted
    • News

  • TGA approves Control Bionic’s autonomous wheelchair for commercial sales after NDIS delays
    TGA approves Control Bionic’s autonomous wheelchair for commercial sales after NDIS delays
    • News

  • Visioneering Technologies NaturalVue contact lenses slow myopia – Study
    • News

    Visioneering Technologies NaturalVue contact lenses slow myopia – Study

    Our eyes are getting worse and worse, and scientists aren’t exactly sure of the reason why. Myopia has exploded in recent decades, especially in East Asia, with the loss in distance vision affecting as many as 90 per cent of students in China. Worldwide as many as 27 per cent of people are nearsighted, and

    Read More
    Public
  • FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering
    • News

    FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering

    Medtech developer Visioneering Technologies (ASX: VTI) may soon have its NaturalVue Multifocal (NVMF) contact lenses re-classified by the FDA which has just approved the first contact lenses which slow the progression of nearsightedness.  The FDA approval was given to CooperVision’s MiSight® 1 day contact lens which slows the progression of myopia specifically in children. The

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.